A comparison of fetal hemoglobin interference in routine high-performance liquid chromatography, immunoassay, and enzymatic methods of glycated hemoglobin measurement.

Sheila X Soh, Tze Ping Loh, Qinde Liu, Hong Liu, Madeline Tjai, Hwee Tong Tan, Tang Lin Teo, Robert C Hawkins, Sunil K Sethi, Lizhen Ong
{"title":"A comparison of fetal hemoglobin interference in routine high-performance liquid chromatography, immunoassay, and enzymatic methods of glycated hemoglobin measurement.","authors":"Sheila X Soh, Tze Ping Loh, Qinde Liu, Hong Liu, Madeline Tjai, Hwee Tong Tan, Tang Lin Teo, Robert C Hawkins, Sunil K Sethi, Lizhen Ong","doi":"10.1093/labmed/lmae109","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Fetal hemoglobin (HbF) is known to cause method-specific interference in glycated hemoglobin A1c (HbA1c) measurement. Data on HbF interference, however, is currently either lacking for some platforms (eg, the Abbott Core Laboratory Alinity c and Beckman Coulter AU5800) or available only for HbF levels lower than the maximum claimed by the manufacturer (eg, Bio-Rad D-100).</p><p><strong>Methods: </strong>We examined the effect of HbF interference on 7 HbA1c platforms using a series of spiked adult whole blood samples with increasing HbF levels (0% to 35%) and either low (approximately 5%) or high (approximately 9%) HbA1c levels, using isotope dilution mass spectrometry as a reference measurement procedure.</p><p><strong>Results: </strong>For the high-performance liquid chromatography (HPLC)-based platforms (Bio-Rad VARIANT II TURBO 2.0 and D-100), relative deviation from expected values was not clinically significant, even at an HbF level of 35%. In contrast, immunoassay (AU5800; Roche Diagnostics cobas c311 and cobas b101; and Siemens Healthineers DCA Vantage) and enzymatic (Alinity c) methods showed clinically significant deviation at HbF levels above 10%.</p><p><strong>Discussion: </strong>Our data suggest that the HPLC methods tested can be used for the majority of patients with elevated HbF. For patients with HbF levels above 10%, immunoassay and enzymatic methods appear to be unsuitable, and alternative HbA1c methods are still advised.</p>","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/labmed/lmae109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Fetal hemoglobin (HbF) is known to cause method-specific interference in glycated hemoglobin A1c (HbA1c) measurement. Data on HbF interference, however, is currently either lacking for some platforms (eg, the Abbott Core Laboratory Alinity c and Beckman Coulter AU5800) or available only for HbF levels lower than the maximum claimed by the manufacturer (eg, Bio-Rad D-100).

Methods: We examined the effect of HbF interference on 7 HbA1c platforms using a series of spiked adult whole blood samples with increasing HbF levels (0% to 35%) and either low (approximately 5%) or high (approximately 9%) HbA1c levels, using isotope dilution mass spectrometry as a reference measurement procedure.

Results: For the high-performance liquid chromatography (HPLC)-based platforms (Bio-Rad VARIANT II TURBO 2.0 and D-100), relative deviation from expected values was not clinically significant, even at an HbF level of 35%. In contrast, immunoassay (AU5800; Roche Diagnostics cobas c311 and cobas b101; and Siemens Healthineers DCA Vantage) and enzymatic (Alinity c) methods showed clinically significant deviation at HbF levels above 10%.

Discussion: Our data suggest that the HPLC methods tested can be used for the majority of patients with elevated HbF. For patients with HbF levels above 10%, immunoassay and enzymatic methods appear to be unsuitable, and alternative HbA1c methods are still advised.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Thrombin-antithrombin complex might be a promising parameter for monitoring anticoagulation in the early postoperative period after LVAD implantation. The mechanisms of resistance, epidemiological characteristics, and molecular evolution of carbapenem-resistant hypervirulent Klebsiella pneumoniae. A comparison of fetal hemoglobin interference in routine high-performance liquid chromatography, immunoassay, and enzymatic methods of glycated hemoglobin measurement. Analytical evaluation of the automated interleukin-6 assay on the Roche cobas e602 analyzer. Identification of biomarkers associated with pathological tumor staging and their utility in the diagnosis and prognosis of prostate cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1